Tech Company Inital Public Offerings
Seres Therapeutics IPO
Seres Therapeutics was acquired by . Shares were listed on 6/26/2015.
Transaction Overview
Company Name
Announced On
6/26/2015
Transaction Type
IPO
Amount
$133,200,000
Proceeds Purpose
We currently estimate that we will use the net proceeds from this offering, together with our existing cash, cash equivalents and investments, as follows: to advance the clinical development of SER-109 for the prevention of further recurrences of CDI in patients suffering from recurrent CDI, which we expect will be sufficient to complete our Phase 2 clinical study; to advance the development of our other product candidates, SER-262, SER-287 and SER-155, which we expect will be sufficient to complete pre-clinical studies and, if supported, file an investigational new drug application, for one or more of these product candidates; and the remainder, if any, to fund current and future research and development activities and for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Sidney St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Seres Therapeutics (NASDAQ: MCRB) is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Roger Pomerantz
Chief Financial Officer
Eric Shaff
Chief Medical Officer
Michele Trucksis
Chief Scientific Officer
David Cook
Chief Technical Officer
John Aunins
VP - Bus. Development
Henry Rath
VP - General Counsel
Thomas DesRosier
VP - Operations
Carol Cullinan
VP - R & D
Matthew Henn
VP - Regulatory Affairs
Barbara McGovern
Browse more venture capital transactions:
Prev: 6/26/2015: Eargo venture capital transaction
Next: 6/26/2015: Conga venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs